@article{0f31088976ee49d3a05535b0909a48b1,
title = "Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial",
author = "Mai, \{Elias K.\} and Axel Nogai and Lokhorst, \{Henk M.\} and \{van der Holt\}, Bronno and Sonja Zweegman and Weisel, \{Katja C.\} and Sandra Croockewit and Anna Jauch and Jens Hillengass and Marian Stevens-Kroef and Raab, \{Marc S.\} and Annemiek Broijl and Bos, \{Gerard M.J.\} and Peter Brossart and Paula Ypma and Christine Hanoun and Uta Bertsch and Thomas Hielscher and Salwender, \{Hans J.\} and Christoph Scheid and Hartmut Goldschmidt and Pieter Sonneveld",
note = "Funding Information: The HOVON-65/GMMG-HD4\textbackslash{}u00A0trial was supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen-Cilag-Ortho Biotech. The German-speaking Myeloma Multicenter Group was supported by grants from Novartis, Amgen (No. P2004-0060), Chugai, and Roche. The investigators thank all participating patients and their families. Further, the authors thank the HOVON trial team, the \textbackslash{}u201CZentrum zur Koordination klinischer Studien (KKS)\textbackslash{}u201D (Heidelberg, Germany), and all participating study sites. Supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen-Cilag-Ortho Biotech. The GMMG was supported by grants from Novartis, Amgen (No. P2004-0060), Chugai, and Roche. Editorial support was provided by Mareike Hampel contracted by the GMMG (Heidelberg University Hospital, Heidelberg, Germany). Open Access funding enabled and organized by Projekt DEAL. Funding Information: The HOVON\textbackslash{}u201065/GMMG\textbackslash{}u2010HD4 trial was supported by the Dutch Cancer Foundation, the German Federal Ministry of Education and Research, and unrestricted Grant No. MMY3003 from Janssen\textbackslash{}u2010Cilag\textbackslash{}u2010Ortho Biotech. The German\textbackslash{}u2010speaking Myeloma Multicenter Group was supported by grants from Novartis, Amgen (No. P2004\textbackslash{}u20100060), Chugai, and Roche.",
year = "2024",
month = nov,
day = "1",
doi = "10.1002/hem3.70052",
language = "English",
volume = "8",
journal = "HemaSphere",
issn = "2572-9241",
publisher = "Wolters Kluwer Health",
number = "11",
}